TY - CHAP
T1 - Lithium safety in the prophylaxis of bipolar disorders
T2 - a study with plasma levels.
AU - Mauri, M. C.
AU - Laini, V.
AU - Scalvini, M. E.
AU - Volonteri, L. S.
AU - Ferrari, M. S.
AU - Panza, G.
PY - 1999/3
Y1 - 1999/3
N2 - From many decades efficacy of lithium salts, as mood stabilizers, has been largely recognized, but their tolerability, in particular during intermediate or long-term treatments is still discussed. The most frequently described side effects can affect several organs. Aim of the study was to evaluate lithium carbonate tolerability after a "brief" (1 month-4 years), "intermediate" (5-9 years) and "longterm" (10-21 years) treatment of patients affected by Bipolar Disorders (BD). 27 patients (14 males, 13 females), aged from 20 to 78 years (mean 49.03 years +/- 14.61 SD), affected by BD, type I, according to DSM IV criteria were included into the study. Our data suggest a good tolerability of lithium salts without significant differences among the three different periods of treatment.
AB - From many decades efficacy of lithium salts, as mood stabilizers, has been largely recognized, but their tolerability, in particular during intermediate or long-term treatments is still discussed. The most frequently described side effects can affect several organs. Aim of the study was to evaluate lithium carbonate tolerability after a "brief" (1 month-4 years), "intermediate" (5-9 years) and "longterm" (10-21 years) treatment of patients affected by Bipolar Disorders (BD). 27 patients (14 males, 13 females), aged from 20 to 78 years (mean 49.03 years +/- 14.61 SD), affected by BD, type I, according to DSM IV criteria were included into the study. Our data suggest a good tolerability of lithium salts without significant differences among the three different periods of treatment.
UR - http://www.scopus.com/inward/record.url?scp=0033085879&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033085879&partnerID=8YFLogxK
M3 - Chapter
C2 - 10827806
AN - SCOPUS:0033085879
VL - 3
SP - 63
EP - 69
BT - European review for medical and pharmacological sciences
ER -